SCHEMBL8313435

SCHEMBL8313435

Fc1ccc(-c2cnc3[nH]cc(-c4cn[nH]c4)c3c2)cc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.71
MAPK9 P45984 1/20 0.71
MAPK10 P53779 1/20 0.71
KIT P10721 4/20 0.66
MAP3K11 Q16584 3/20 0.65
DYRK1A Q13627 5/20 0.63
CLK1 P49759 3/20 0.63
DYRK2 Q92630 3/20 0.63
DYRK1B Q9Y463 3/20 0.63
CLK2 P49760 1/20 0.63
CLK4 Q9HAZ1 1/20 0.63
CCNT1 O60563 1/20 0.58
CCNA2 P20248 1/20 0.58
CDK2 P24941 1/20 0.58
CDK9 P50750 1/20 0.58
TNIK Q9UKE5 2/20 0.57
AXL P30530 2/20 0.57
CDK8 P49336 1/20 0.57
NTRK1 P04629 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8941778 0.89 DYRK1A (0.77) KITMAP3K11DYRK1ACLK1DYRK2
SCHEMBL14049065 0.86 DYRK1A (0.79) MAPK8MAPK9MAPK10DYRK1ACLK1
SCHEMBL8313442 0.84 KIT (0.72) MAPK8MAPK9MAPK10KITMAP3K11
SCHEMBL12829496 0.84 MAPK8 (0.64) MAPK8MAPK9MAPK10KITMAP3K11
SCHEMBL8320989 0.83 AXL (0.83) KITMAP3K11DYRK1ACLK1DYRK2
SCHEMBL8320088 0.83 KIT (0.68) MAPK8MAPK9MAPK10KITMAP3K11
SCHEMBL4406366 0.83 MAPK8 (1.00) MAPK8MAPK9MAPK10KITMAP3K11
SCHEMBL8320085 0.82 AXL (0.76) MAPK8MAPK9MAPK10MAP3K11DYRK1A
SCHEMBL8941722 0.82 KIT (0.74) KITMAP3K11DYRK1ACLK1DYRK2
SCHEMBL8317528 0.81 SGK1 (0.74) MAPK8MAPK9MAPK10MAP3K11DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295433-A2 JNK inhibitors Eisai R&D Management Co., Ltd. (JP) 2011-03-16 EP disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 MAPK8 50/4885MAPK9 43/4885MAPK10 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.